Literature DB >> 17997266

A categorical typology of naltrexone-adopting private substance abuse treatment centers.

Carrie B Oser1, Paul M Roman.   

Abstract

This study used a diffusion of innovations theoretical framework [Rogers, E. M. 2003. Diffusion of innovations. 5th edition. New York: The Free Press] to identify organizational-level predictors of a categorical typology of substance abuse treatment centers based on naltrexone adoption. Data from the National Treatment Center Study (N = 158) were used to examine the impact of socioeconomic status, organizational personality, and communication behavior on adopter categorization (i.e., innovators, early adopters, early majority, late majority, or laggards). Results from the ordered logistic regression model indicate that organizations that did not have onsite 12-step meetings and were familiar with treatment innovations were more likely to be in a more innovative category. Organizations that learned about innovations from professional development seminars and informal conversations with external treatment providers were more likely to be in a less innovative category. Identifying and targeting the early and late majority categories of adopting organizations for better training and community linkages could help reduce the research-to-practice gap.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997266      PMCID: PMC2682460          DOI: 10.1016/j.jsat.2007.08.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  30 in total

1.  Innovation in nursing homes: which facilities are the early adopters?

Authors:  N G Castle
Journal:  Gerontologist       Date:  2001-04

2.  Prescribing new drugs: qualitative study of influences on consultants and general practitioners.

Authors:  M I Jones; S M Greenfield; C P Bradley
Journal:  BMJ       Date:  2001-08-18

3.  A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.

Authors:  J Chick; R Anton; K Checinski; R Croop; D C Drummond; R Farmer; D Labriola; J Marshall; J Moncrieff; M Y Morgan; T Peters; B Ritson
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

4.  Substance user treatment program quality: selected topics.

Authors:  Stephen Magura; Sam Schildhaus; Andrew Rosenblum; David Gastfriend
Journal:  Subst Use Misuse       Date:  2002 Jun-Aug       Impact factor: 2.164

5.  Assessing organizational readiness for change.

Authors:  Wayne E K Lehman; Jack M Greener; D Dwayne Simpson
Journal:  J Subst Abuse Treat       Date:  2002-06

6.  Obstacles to answering doctors' questions about patient care with evidence: qualitative study.

Authors:  John W Ely; Jerome A Osheroff; Mark H Ebell; M Lee Chambliss; Daniel C Vinson; James J Stevermer; Eric A Pifer
Journal:  BMJ       Date:  2002-03-23

7.  Naltrexone in the treatment of alcohol dependence.

Authors:  J H Krystal; J A Cramer; W F Krol; G F Kirk; R A Rosenheck
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

8.  Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.

Authors:  R F Anton; D H Moak; L R Waid; P K Latham; R J Malcolm; J K Dias
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

9.  Naltrexone treatment in a jail work-release program.

Authors:  L S Brahen; R K Henderson; T Capone; N Kordal
Journal:  J Clin Psychiatry       Date:  1984-09       Impact factor: 4.384

10.  Adoption and implementation of new technologies in substance abuse treatment.

Authors:  Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2002-06
View more
  22 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  The substance abuse counseling workforce: education, preparation, and certification.

Authors:  Traci Rieckmann; Christiane Farentinos; Carrie J Tillotson; Jonathan Kocarnik; Dennis McCarty
Journal:  Subst Abus       Date:  2011-10       Impact factor: 3.716

4.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.

Authors:  Paul M Roman; Amanda J Abraham; Hannah K Knudsen
Journal:  Addict Behav       Date:  2011-01-27       Impact factor: 3.913

5.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

6.  Climate for innovation, 12-step orientation, and tobacco cessation treatment.

Authors:  Jessica L Muilenburg; Tanja C Laschober; Lillian T Eby
Journal:  J Subst Abuse Treat       Date:  2013-11-12

7.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

8.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

9.  Training community-based treatment providers to implement contingency management for opioid addiction: Time to and frequency of adoption.

Authors:  Sarah A Helseth; Tim Janssen; Kelli Scott; Daniel D Squires; Sara J Becker
Journal:  J Subst Abuse Treat       Date:  2018-09-11

10.  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2009-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.